[
    [
        {
            "time": "2018-03-15",
            "original_text": "UPDATE 1-J&J blockbuster loses ground to biosimilars despite Quebec court ruling",
            "features": {
                "keywords": [
                    "J&J",
                    "blockbuster",
                    "loses ground",
                    "biosimilars",
                    "Quebec court ruling"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "Should Investors Add Johnson & Johnson Stock to Their Shopping Lists?",
            "features": {
                "keywords": [
                    "Investors",
                    "Johnson & Johnson",
                    "Stock",
                    "Shopping Lists"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "UPDATE 1-N.Y. insurance regulator notifies opioid makers, distributors of enforcement action -sources",
            "features": {
                "keywords": [
                    "N.Y.",
                    "insurance regulator",
                    "opioid makers",
                    "distributors",
                    "enforcement action"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "insurance"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3",
            "features": {
                "keywords": [
                    "Halozyme",
                    "Earnings",
                    "Revenues",
                    "Miss Estimates",
                    "Q3"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 1,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "J&J's Remicade losing ground in Quebec health plan despite court victory",
            "features": {
                "keywords": [
                    "J&J",
                    "Remicade",
                    "losing ground",
                    "Quebec health plan",
                    "court victory"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]